

Offices at CHENNAI- COIMBATORE - MUMBAI –BANGALORE

Limited Review Report

Review Report to
The Board of Directors,
MONO PHARMACARE LIMITED

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results ('the Statement') of **MONO PHARMACARE LIMITED** ("the Company") for the half year ended September 30, 2024, prepared and being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The preparation of the Statement is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement of Unaudited Financial Results based on our review.

We conducted our review in accordance with the Standard on Review Engagement-(SRE) 2410, on "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KUMBHAT & CO LLP
Chartered Accountants

Firm Regn. No. S000162/001609S

**Gaurang
Champaklal
Unadkat**

Digitally signed by
Gaurang Champaklal
Unadkat
Date: 2024.11.14
18:49:54 +05'30'

Gaurang C. Unadkat
Partner

Mem.No. 131708

UDIN: 24131708BKBKJI1010

Place: Mumbai
Dated: November 14th, 2024

MONO PHARMACARE LIMITED

Registered Office: 1A, Krinkal Apartment, Opp. Mahalaxmi Temple, Paldi, Ahmedabad, Gujarat, Pin-380007

CIN: U24304GJ2022PLC136193

Website: www.monopharmacareLtd.com

Email: info@monopharmacareLtd.com

Standalone Statement of Assets and Liabilities as at September 30, 2024

(Rs. in Lakhs)

	Particulars	As at September 30th, 2024 (Unaudited)	As at March 31st, 2024 (Audited)
I.	EQUITY AND LIABILITIES		
(1)	Shareholders' Funds		
	(a) Share Capital	1766.86	1766.86
	(b) Reserve and surplus	1273.33	1044.04
		3040.19	2810.90
(2)	Non-current liabilities		
	(a) Long-term borrowings	864.80	433.53
	(b) Long-term Provisions	6.79	4.29
		871.59	437.82
(3)	Current Liabilities		
	(a) Short Term Borrowings	924.25	893.46
	(b) Trade Payables	968.68	291.73
	(c) Other Current Liabilities	108.48	79.47
	(d) Short-term Provisions	90.97	26.95
		2092.38	1291.61
	TOTAL EQUITY AND LIABILITIES	6004.15	4540.32
II.	ASSETS		
(1)	Non Current Assets		
	(a) Property, Plants & Equipment		
	(i) Tangible Assets	19.36	12.95
	(ii) Inangible Assets	1.17	1.34
	(iii) Capital WIP	1.80	
	(b) Non-Current Investments	679.94	359.49
	(c) Deferred tax assets (Net)	1.94	1.17
	(d) Long-term loans and advances	1.45	1.45
		705.66	376.40
(2)	Current Assets		
	(a) Inventories	2475.44	2099.31
	(b) Trade Receivables	2595.04	1744.21
	(c) Cash and Cash Equivalents	5.76	25.05
	(d) Short Term Loans and Advances	148.74	227.62
	(e) Other Current Assets	73.51	67.72
		5298.49	4163.92
	TOTAL ASSETS	6004.15	4540.32

For and on behalf of the Board of Directors
Mono Pharmacare LimitedPanilam S. Lakhataria
Chairman & Managing Director
DIN: 07659275

Place: Ahmedabad

Date: November 14th, 2024

MONO PHARMACARE LIMITED

Registered Office: 1A, Krinkal Apartment, Opp. Mahalaxmi Temple, Paldi, Ahmedabad, Gujarat, Pin-380007

CIN: U24304GJ2022PLC136193

Website: www.monopharmacareLtd.com

Email: info@monopharmacareLtd.com

Statement of Unaudited Standalone Financial Results for the Half Year ended on September 30, 2024

		(Rs. in Lakhs)		
Particulars	For the Half Year Ended			For the Year Ended on
	September 30, 2024	March 31, 2024	September 30, 2023	March 31, 2024
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
I Revenue from operation	4438.32	3612.12	3459.87	7071.99
II Other income	78.39	91.81	77.84	169.66
III Total Revenue (I + II)	4516.71	3703.93	3537.71	7241.65
IV Expenses				
Purchase of Traded Goods	4326.19	3474.93	3546.65	7021.58
(Increase)/Decrease in Stock	-376.13	-130.47	-450.72	-581.19
Employee Benefits Expenses	118.74	138.89	105.65	244.53
Finance Cost	59.34	63.67	57.64	121.31
Depreciation and Amortisation Cost	3.17	4.12	3.75	7.87
Other expenses	104.88	87.21	54.68	141.89
Total Expenses	4236.19	3638.35	3317.64	6955.99
Profit before tax Extraordinary and Exceptional Items (III - IV)				
V Exceptional Items	280.51	65.59	220.07	285.66
VI Extraordinary Items And Tax (V- VI)	0.00	0.00	0.00	0.00
Prior Period Expenses	0.00	0.00	0.00	0.00
VIII Profit Before Tax	280.51	65.59	220.07	285.66
IX Tax Expenses				
(1) Current Tax	52.00	-0.80	38.30	37.50
(2) Deferred Tax	-0.78	8.69	-4.76	3.92
X Profit (Loss) for the Period	229.29	57.70	186.54	244.24
XI Earning per Equity share :				
(1) Basic	1.30	0.38	1.43	1.59
(2) Diluted	1.30	0.38	1.43	1.59

Notes:

- The above results were reviewed and recommended by the Audit Committee, at its meeting held on November 14 th ,2024 for approval by the Board and these results were approved and taken on record at the meeting of the Board of Directors of the Company held on that date. The above result is subjected to Limited Review by the Statutory Auditors of the Company, as required under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements)
- The Company is listed on the SME platform of the National Stock Exchange of India Limited and the provisions of the IND AS as per rule 4 of the Companies (Indian Accounting Standards) Rules, 2015, Reconciliation of Profit and Loss and Reconciliation of Equity does not apply to the company and hence not reported.
- Segment Reporting : The company is in the business of distribution of pharmaceutical items. Therefore disclosures under Accounting Standard 17- Primary Segment Reporting is not applicable. Secondary segmental reporting on the basis of the geographical location of the customers is as below :

Standalone Figures					
		(Rs.in Lakhs)			
Sr.No	Particulars	Half Year ended on		Year ended on	
		Sept 30, 2024	March 31, 2024	Sept 30, 2023	March 31, 2024
1	India	4438.32	3603.71	3459.87	7063.58
2	Rest of the World	-	8.41	-	8.41
	Total	4438.32	3612.12	3459.87	7071.99

4. The information presented above is extracted from the unaudited Standalone Financial Statements for the Half ended September 30th, 2024, and are prepared in accordance with the Accounting Standards as issued by the Institute of Chartered Accountants of India and as specified in Section 133 of the Companies Act, 2013 and the relevant rules thereof.

5. The figures for the preceding half year ended on 31st March, 2024 as reported in these financial result, are the balancing figures between audited figures in respect of the full financial year ended on 31st March, 2024 and based on the Management Certified Accounts which are not subjected to Limited Review by the Statutory Auditors.

6. The company came with an Initial Public Offer of equity shares on 28th Aug., 2023 and closed on August 30,2023. The initial public offer ("IPO") was for 53,00,000 equity shares of face value of Rs. 10 each at premium of Rs. 18 per share aggregating to INR 1484.00 lakhs. The shares of the company were listed on the National Stock Exchange of India Limited, Emerge Platform on September 7, 2023

7. The details of utilization of IPO Proceeds are as per the table set forth below:

S. No.	Particulars	Projected Utilization of proceeds as per prospectus	Actual Utilization of proceeds upto 30-09-2024	Pending for Utilization of proceeds upto 30-09-2024
1	Working Capital Requirements	898.00	898.00	-
2	General Corporate Purpose	366.00	252.16	113.84
3	Issue expenses	220.00	220.00	-
	Total Proceeds from the Issue	1484.00	1370.16	113.84

8. The above financial results are available on the website of the company i.e. www.monopharmacareLtd.com and on the website of emerge platform of National Stock Exchange i.e. www.nseindia.com

9. Figures for previous half year/ year have been regrouped wherever necessary.

For and on behalf of the Board of Directors
Mono Pharmacare Limited



Panilam S. Lakhatariya
Chairman & Managing Director
DIN: 07659275

Place: Ahmedabad

Date: November 14th, 2024

MONO PHARMACARE LIMITED

Registered Office: 1A, Krinkal Apartment, Opp. Mahalaxmi Temple, Paldi, Ahmedabad, Gujarat, Pin-380007

CIN: U24304GJ2022PLC136193

Website: www.monopharmacareLtd.com

Email: info@monopharmacareLtd.com

Standalone Cash Flow statement as at September 30, 2024

(Rs. in Lakhs)

Particulars	As at September 30th, 2024 (Unaudited)	As at March 31st, 2024 (Audited)
Cash flow from operating activities		
Profit/(loss) before tax	280.51	285.66
Non-cash adjustments to reconcile profit before tax to net cash flows		
Depreciation	3.17	7.87
Finance Cost	59.34	121.31
Operating profit/(loss) before working capital changes	343.03	414.83
Movements in working capital:		
Increase/(decrease) in trade payables	676.95	82.40
Increase/(decrease) in other current liabilities	29.01	17.53
Increase/(decrease) in short term provision	64.02	-17.90
Increase/(decrease) in short term borrowings	30.79	-13.59
Decrease/(increase) in Inventories	-376.13	-581.19
Decrease/(increase) in trade receivables	-850.83	-935.82
Decrease/(increase) in short-term loans and advances	78.88	81.04
Decrease/(increase) in other Current Assets	-5.78	-41.45
Cash generated from Operations	-10.06	-994.14
Less: Direct taxes paid	-52.00	-37.50
Net Cash from Operating Activities (A)	-62.06	-1031.64
Cash flows from investing activities		
Sale/(Purchase) of Fixed Assets	-11.21	-3.00
Purchase of Investment	-320.44	-162.94
Net cash flow from/(used in) investing activities (B)	-331.65	-165.94
Cash flow from financing activities		
Acceptance / (Repayment) of Long Term Loan	431.26	90.05
Payment / (Repayment) of Long term Loan advance	0.00	0.00
Long term Provision	2.50	4.29
Proceeds from issue of equity shares	0.00	530.00
Securities Premium on Allotment of Equity Shares	0.00	954.00
Utilised for IPO Expenses	0.00	-257.26
Finance Cost	-59.34	-121.31
Net cash flow from/(used in) financing activities (C)	374.42	1199.78
Net increase/(decrease) in cash and cash equivalents (A+B+C)	-19.29	2.19
Cash and cash equivalents at the beginning of the year	25.05	22.86
Cash and cash equivalents at the end of the year	5.76	25.05
Net increase/(decrease) in cash and cash equivalents	-19.29	2.19

For and on behalf of the Board of Directors
Mono Pharmacare Limited
Panilam S. Lakhataria
Chairman & Managing Director
DIN: 07659275

Place: Ahmedabad

Date: November 14th, 2024

Offices at CHENNAI- COIMBATORE - MUMBAI –BANGALORE

Limited Review Report

Review Report to
The Board of Directors,
MONO PHARMACARE LIMITED

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results ('the Statement') of **MONO PHARMACARE LIMITED** ('the Parent') ('the Company') and its Subsidiary Company for the half year ended September 30, 2024, prepared and being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The preparation of the Statement is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Consolidated Statement of Unaudited Financial Results based on our review.

We conducted our review in accordance with the Standard on Review Engagement-(SRE) 2410, on "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognised accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Mumbai
Dated: November 14th, 2024

For KUMBHAT & CO LLP
Chartered Accountants
Firm Regn. No. S000162/001609S
Gaurang
Champaklal
Unadkat
Digitally signed by
Gaurang Champaklal
Unadkat
Date: 2024.11.14
18:51:51 +05'30'
Gaurang C. Unadkat
Partner
Mem.No. 131708
UDIN: 24131708BKBIJG8181

MONO PHARMACARE LIMITED

Registered Office: 1A, Krinkal Apartment, Opp. Mahalaxmi Temple, Paldi, Ahmedabad, Gujarat, Pin-380007


CIN: U24304GJ2022PLC136193

Website: www.monopharmacareLtd.com

Email: info@monopharmacareLtd.com

Consolidated Statement of Assets and Liabilities as at September 30th, 2024**(Rs. in Lakhs)**

Sr.No.	Particulars	As at September 30,2024 (Unaudited)	As at March 31,2024 (Audited)
I.	EQUITY AND LIABILITIES		
(1)	Shareholders' Funds		
	(a) Share Capital	1769.55	1768.80
	(b) Reserve and surplus	1270.64	1042.10
(2)	Minority Interest	2.69	1.94
		3042.88	2812.84
(3)	Non-current liabilities		
	(a) Long-term borrowings	2191.62	1712.49
	(b) Long-term Provision	6.79	4.29
		2198.41	1716.78
(4)	Current Liabilities		
	(a) Short Term Borrowings	2679.47	2431.55
	(b) Trade Payables	1728.81	968.51
	(c) Other Current Liabilities	135.74	119.35
	(d) Short-term Provisions	166.28	62.25
		4710.30	3581.66
	TOTAL EQUITY AND LIABILITIES	9951.59	8111.27
II.	ASSETS		
(1)	Non Current Assets		
	(a) Property, Plants & Equipment		
	(i) Tangible Assets	97.25	89.90
	(ii) Intangible Assets	1.17	1.34
	(iii) Capital Work In Progress	1.80	-
	(b) Non-Current Investments	-	-
	(c) Deferred tax assets (Net)	1.94	1.17
	(d) Long-term loans and advances	2.50	2.50
		104.66	94.91
(2)	Current Assets		
	(a) Inventories	4774.31	4229.26
	(b) Trade Receivables	4584.24	3159.03
	(c) Cash and Cash Equivalent	13.11	36.27
	(d) Short Term Loans and Advances	360.49	471.49
	(e) Other Current Assets	114.77	120.32
		9846.92	8016.36
	TOTAL ASSETS	9951.59	8111.27

For and on behalf of the Board of Directors
Mono Pharmacare Limited
Panilam S. Lakhatariya
Chairman & Managing Director

DIN: 07659275

Place: Ahmedabad

Date: November 14th, 2024

MONO PHARMACARE LIMITED

Registered Office: 1A, Krinkal Apartment, Opp. Mahalaxmi Temple, Paldi, Ahmedabad, Gujarat, Pin-380007

CIN: U24304GJ2022PLC136193

Website: www.monopharmacareLtd.com

Email: info@monopharmacareLtd.com

Statement of Unaudited Consolidated Financials Results for the Half Year ended on September 30 th,2024

(Rs. in Lakhs)

Sr.No.	Particulars	September 30,2024	March 31,2024	September 30,2023	For the year ended
		(Unaudited)	(Audited)	(Unaudited)	March 31,2024
					(Audited)
I	Revenue from operation	8716.28	5580.90	6653.12	12234.02
II	Other income	4.27	6.04	3.50	9.54
III	Total Revenue (I + II)	8720.55	5586.94	6656.62	12243.56
IV	Expenses				
	Purchase of Traded Goods	8480.82	5415.91	6612.34	12028.25
	(Increase)/Decrease in Stock	-545.06	-378.35	-582.30	-960.65
	Employee Benefits Expenses	170.21	170.10	181.29	351.39
	Finance Cost	156.31	158.63	149.67	308.29
	Depreciation and Amortisation Cost	6.42	6.42	5.11	11.52
	Other expenses	136.64	127.47	54.68	182.15
	Total Expenses	8405.34	5500.18	6420.78	11920.95
V	Profit before tax Extraordinary and Exceptional Items (III - IV)	315.21	86.76	235.85	322.60
VI	Exceptional Items	0.00	0.00	0.00	0.00
VII	Extraordinary Items And Tax (V- VI)				
	Prior Period Expenses	0.00	0.00	0.00	0.00
VIII	Profit Before Tax	315.21	86.76	235.85	322.60
IX	Tax Expenses				
	(1) Current Tax	85.95	19.50	53.30	72.80
	(2) Deferred Tax	0.78	8.69	-4.76	3.92
X	Profit (Loss) for the Year	230.04	58.57	187.31	245.88
XI	Minority Interest	-0.75	-0.88	-0.77	-1.65
XII	<u>Profit/(Loss) for the year after Taxes and Minority Interest</u>	229.29	57.70	186.54	244.24
XIII	Earning per Equity share :				
	(1) Basic	1.30	0.38	1.43	1.58
	(2) Diluted	1.30	0.38	1.43	1.58

Notes:

1.The above results were reviewed and recommended by the Audit Committee, at its meeting held on 14th November,2024 for approval by the Board and these results were approved and taken on record at the meeting of the Board of Directors of the Company held on that date. The above result is subjected to Limited Review by the Statutory Auditors of the Company, as required under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2.The above consolidated financial result include two subsidiary firms wherein the company holds 99% of the partner's capital of M/s. Ahmedabad Medical Corporation and M/s. Supal Distributors LLP.

3.Segment Reporting : The company is in the business of distribution of pharmaceutical items. Therefore disclosures under Accounting Standard 17- Primary Segment Reporting is not applicable.Secondary segmental reporting on the basis of the geographical location of the customers is as below :

Consolidated Figures					
(Rs.in Lakhs)					
Sr. No	Particulars	Half Year ended on			Year ended on
		Sept 30, 2024	March 31, 2024	Sept 30, 2023	March 31, 2024
1	India	8716.28	5580.90	6653.12	12225.61
2	Rest of the World	-	8.41	-	8.41
	Total	8716.28	5589.31	6653.12	12234.02

4. The information presented above is extracted from the unaudited Consolidated Financial Statements for the Half ended September 30th, 2024, and are prepared in accordance with the Accounting Standards as issued by the Institute of Chartered Accountants of India and as specified in Section 133 of the Companies Act, 2013 and the relevant rules thereof.

5. The information presented above is extracted from the Audited Standalone Financial Statements for the financial year ended 31st March, 2024, and are prepared in accordance with the Accounting Standards as issued by the Institute of Chartered Accountants of India and as specified in Section 133 of the Companies Act, 2013 and the relevant rules thereof.

6. The figures for the preceding half year ended on 31st March, 2024 as reported in these financial result, are the balancing figures between audited figures in respect of the full financial year ended on 31st March, 2024 and based on the Management Certified Accounts which are not subjected to Limited Review by the Statutory Auditors.

7. The above financial results are available on the website of the company i.e. www.monopharmacareltd.com and on the website of emerge platform of National Stock Exchange i.e. www.nseindia.com

8. Figures for previous half year/ year have been regrouped wherever necessary.

**For and on behalf of the Board of Directors
Mono Pharmacare Limited**

Panilam S. Lakhatariya
Chairman & Managing Director
DIN: 07659275

Place: Ahmedabad

Date: November 14th, 2024

MONO PHARMACARE LIMITED

Registered Office: 1A, Krinkal Apartment, Opp. Mahalaxmi Temple, Paldi, Ahmedabad, Gujarat, Pin-380007

CIN: U24304GJ2022PLC136193

Website: www.monopharmacareLtd.com

Email: info@monopharmacareLtd.com

Consolidated Statement of Cash Flow as at September 30, 2024

Particulars	(Rs. in Lakhs)	
	As at September 30, 2024 (Unaudited)	As at March 31, 2024 (Audited)
Cash flow from operating activities		
Profit/(loss) before tax		
Non-cash adjustments to reconcile profit before tax to net cash flows	315.21	322.60
Depreciation		
Finance Cost	6.42	11.52
Operating profit/(loss) before working capital changes	156.31	308.29
Movements in working capital:	477.94	642.42
Increase/(decrease) in trade payables	760.30	292.56
Increase/(decrease) in other current liabilities	16.39	1.34
Increase/(decrease) in short term provision	104.03	-13.60
Increase/(decrease) in short term borrowings	247.92	182.81
Decrease/(increase) in Inventories	-545.06	-960.64
Decrease/(increase) in trade receivables	-1425.22	-971.96
Decrease/(increase) in short-term loans and advances	111.00	63.88
Decrease/(increase) in other Current Assets	5.55	-41.00
Cash generated from Operations	-247.14	-804.18
Less: Direct taxes paid	-85.95	-73.00
Net Cash from Operating Activities (A)	-333.09	-877.18
Cash flows from investing activities		
Sale/(Purchase) of Fixed Assets	-13.60	-17.51
Purchase of Investment	0.00	57.34
Net cash flow from/(used in) investing activities (B)	-13.60	39.84
Cash flow from financing activities		
Acceptance / (Repayment) of Long Term Loan	479.13	-88.55
Increase/(Decrease) in Long term Provision	2.50	
Increase in Share Capital		531.94
Increase in Security Premium		696.74
Increase/(Decrease) in Capital Work In Progress	-1.80	
Finance Cost	-156.31	-308.29
Net cash flow from/(used in) financing activities (C)	323.52	831.84
Net increase/(decrease) in cash and cash equivalents (A+B+C)	-23.16	-5.50
Cash and cash equivalents at the beginning of the year	36.27	41.77
Cash and cash equivalents at the end of the year	13.11	36.27
Net increase/(decrease) in cash and cash equivalents	-23.16	-5.50

For and on behalf of the Board of Directors
Mono Pharmacare Limited
Panilam S. Lakhatriya
Chairman & Managing Director
DIN: 07659275

Place: Ahmedabad

Date: November 14th, 2024